<DOC>
	<DOCNO>NCT02857361</DOCNO>
	<brief_summary>The study look whether preferable administer two wafer simultaneously separately .</brief_summary>
	<brief_title>Crossover Study Evaluate PK Effects Two Different Wafer Administration Protocols .</brief_title>
	<detailed_description />
	<mesh_term>Ketamine</mesh_term>
	<criteria>Males female age 1865 year . Good general health without clinically significant renal , hepatic , cardiac respiratory disease , determine Principal Investigator . Willing able give inform consent agree complete study procedure . Have suitable venous access blood sampling . Female participant eligible follow apply : 1 . Not pregnant ( woman child bear potential must negative serum pregnancy test screen negative urine pregnancy test checkin inpatient period ) ; 2 . Not lactate ; 3 . Not plan become pregnant study ; 4 . Be surgically sterile ( irreversible surgical sterilisation hysterectomy , bilateral oophorectomy , bilateral salpingectomy ) , undergone bilateral tubal ligation ; least two year postmenopausal ; practice doublebarrier contraception use insertable , injectable , transdermal , combination oral contraceptive great 2 month prior screen visit commits use acceptable form highly effective birth control duration study 30 day last dose study drug administration . BMI within range 1930 kg/m2 ( inclusive ) . Deemed able read understand English order communicate research staff complete protocol require questionnaire form . Has laboratory value Screening Visit outside normal range , unless judge Investigator clinically significant appropriate evaluation . One repeat initial laboratory testing allow . AST , ALT ALP test excess 1.5 time upper limit normal . Any gastrointestinal condition could affect drug absorption . History clinically significant condition involve bladder urinary tract , include frequent urinary tract infection ( e.g . &gt; 2 per year ) , current symptom bladder irritation frequent urgent need urinate burning urination . History ( within last six month ) current clinically significant psychiatric disorder include anxiety , psychosis depression . Current inflammatory ulcerative disease oral cavity could impair absorption sublingual medication . History severe allergic anaphylactic drugrelated reaction . History hypersensitivity ketamine excipients Wafermineâ„¢ . Intake prescribed OverTheCounter ( OTC ) /nonprescribed drug , vitamin , supplement herbal medicine , within 2 week administration investigational product ( long medication halflife long enough potentially expose healthy participant significant systemic exposure ) . Exception : Hormone replacement therapy oral contraceptive female participant allow . Use drug enzymeinducing property , rifampicin St John 's Wort , within 3 week 5 halflives , whichever great , prior treatment period 1 throughout study , drug know strong inhibitor CYP3A4 within 5 halflives treatment period 1 throughout study . Participation another clinical trial investigational agent within 30 day screen . Positive serology hepatitis C virus ( HCV ) , hepatitis B human immunodeficiency virus ( HIV ) . Clinically significant , determined Investigator , abnormal ECG ( 12lead ) vital sign screen visit predose treatment day . Known suspect drug ( include analgesic drug tranquilizer ) alcohol abuse dependence , define DSMIV , full remission , judge Investigator , history alcohol abuse excessive intake alcohol , define regular weekly intake &gt; 15 unit men &gt; 10 unit woman . ( 1 unit = 25 mL spirit , 125 mL wine , 250 mL beer lager . ) Positive result urine drug screen breath alcohol test screen and/or predose . A positive result urinary drug screen screen allow discretion Investigator provide result reliably explain recent medication and/or dietary history . Significant history illicit drug use ( determined Investigator ) . Any alcohol use within 24 hour prior inpatient treatment period . Unwillingness inability comply requirement protocol , include presence condition ( physical , mental , social ) likely affect participant return subsequent visit schedule . Blood donation ( 1 unit ) within 1 month prior screen visit end study participation . Current previous tobacco user ( within 12 month prior screen ) . Participants routinely consume four standard caffeinated beverage per 24hour period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>